Article
Characterization ofCHEK2 mutations in prostate cancer
1 Jan 2006
Abstract excerpt
The checkpoint kinase 2 (CHEK2, also known as CHK2) is a tumor suppressor that participates in the DNA damage-signaling pathway. It is phosphorylated and activated following DNA damage, resulting in cell cycle arrest and apoptosis. Previously, we reported germline CHEK2 mutations in patients with prostate cancer. In this study, we have identified two novel somatic CHEK2 mutations, c.349A > G (p.R117G) and c.967A...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
